- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00296790
Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)
October 11, 2007 updated by: Sanofi
A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs.
Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).
Study Overview
Study Type
Interventional
Enrollment
372
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- Male or female between the ages of 21and 64 years, inclusive;
- Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization;
- Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders;
- Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)
- Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety.
- Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data.
- Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry.
EXCLUSION
- History of Post-Traumatic Stress Disorder;
- Concomitant Major Depressive Disorder or Bipolar Disorder;
- Any abnormal pre-study laboratory values that require clinical intervention
- Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous month.
- Pregnant or breastfeeding
- History of drug addiction, alcoholism, or drug abuse
- Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
- A positive urine drug screen for compounds that would interfere with the assessment of a hypnotic.
- Use of prescription and non-prescription sedative drugs;
- Prior failure to respond to escitalopram therapy for anxiety
- The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
- History of sleep apnea
- History of myasthenia gravis
- Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem or escitalopram or any of their excipients
- Subject is currently participating in another clinical trial (or within 28 days of screening).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Study Completion
February 1, 2007
Study Registration Dates
First Submitted
February 23, 2006
First Submitted That Met QC Criteria
February 23, 2006
First Posted (Estimate)
February 27, 2006
Study Record Updates
Last Update Posted (Estimate)
October 12, 2007
Last Update Submitted That Met QC Criteria
October 11, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- PM_L_0167
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.